Skip to search formSkip to main contentSkip to account menu

177Lu-PSMA-617

Known as: 177Lu-617-prostate-specific membrane antigen ligand 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DipeptidesHeterocyclic Compounds, 1-Ring

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Re: Long Term Follow-up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant…
2019
2019
LBA-25 RESIST-PC PHASE 2 TRIAL: 177LU-PSMA-617 RADIONUCLIDE THERAPY FOR METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
INTRODUCTION AND OBJECTIVES: Introduction: This is an investigator-initiated open-label prospective bi-centric single-arm phase 2… 
2019
2019
Op metastasen gerichte behandeling van prostaatcarcinoom
Het aantal behandelmogelijkheden voor gemetastaseerd prostaatkanker en castratieresistent prostaatkanker is het laatste decennium… 
2019
2019
Ciblage du PSMA et du GRPR dans le diagnostic initial de cancer de prostate : étude comparative en micro-imagerie tissulaire avec l’111In-PSMA-617 et l’111In-RM2
2018
2018
Prognostic value of baseline imaging parameters prior to therapy with Lu-177-PSMA-617
Highly Cited
2016
Highly Cited
2016
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific membrane antigen (177Lu-PSMA) is performed in… 
Review
2016
Review
2016
Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in treatment of patients with castration resistant prostate cancer
1017 Objectives The objective of this study was to evaluate the radiation dosimetry of 177Lu- prostate specific membrane antigen… 
2016
2016
Investigation of a hybrid image approach and a reduction in the number of blood samples for a decreased clinical workload for patient-specific bone marrow dosimetry in Lu-177-DKFZ-PSMA-617 therapy
2016
2016
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy and quality of life assessment
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)